Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

December 19, 2023

https://www.globenewswire.com/news-release/2023/12/18/2798131/0/en/Sight-Sciences-Announces-the-Publication-of-Successful-Results-of-the-SAHARA-Randomized-Controlled-Clinical-Trial-Comparing-TearCare-to-Restasis-for-the-Treatment-of-Dry-Eye-Diseas.html

MENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq:SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the publication in Clinical Ophthalmology of the six-month primary results from the SAHARA randomized controlled trial (“RCT”).

Read more at globenewswire.com

Related news for (SGHT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.